PL408335A1 - Application of phospholipide preparation from egg yolk - Google Patents
Application of phospholipide preparation from egg yolkInfo
- Publication number
- PL408335A1 PL408335A1 PL408335A PL40833514A PL408335A1 PL 408335 A1 PL408335 A1 PL 408335A1 PL 408335 A PL408335 A PL 408335A PL 40833514 A PL40833514 A PL 40833514A PL 408335 A1 PL408335 A1 PL 408335A1
- Authority
- PL
- Poland
- Prior art keywords
- egg yolk
- preparation
- phospholipide
- application
- lecithin
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- 102000002322 Egg Proteins Human genes 0.000 title abstract 2
- 108010000912 Egg Proteins Proteins 0.000 title abstract 2
- 235000013345 egg yolk Nutrition 0.000 title abstract 2
- 210000002969 egg yolk Anatomy 0.000 title abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 2
- 235000015872 dietary supplement Nutrition 0.000 abstract 2
- 229940067606 lecithin Drugs 0.000 abstract 2
- 235000010445 lecithin Nutrition 0.000 abstract 2
- 239000000787 lecithin Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 238000011301 standard therapy Methods 0.000 abstract 1
- 230000009469 supplementation Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Wynalazek dotyczy zastosowania preparatu fosfolipidowego z żółtka jaj, zwanego super lecytyną, do wytwarzania leku lub jako substancja czynna leku przeciwzapalnego niesteroidowego do stosowania przy leczeniu, łagodzeniu lub profilaktyce stanów zapalnych oraz chorób o podłożu zapalnym, zwłaszcza takich jak choroby nowotworowe, otyłość, cukrzyca, nadciśnienie tętnicze, miażdżyca. Rozwiązanie obejmuje również zastosowania super lecytyny jako środka farmaceutycznego, suplementu diety, dodatku żywieniowego lub jako składnika preparatów złożonych do stosowania w profilaktyce i uzupełnieniu standardowej terapii leczenia tych chorób.The invention relates to the use of a phospholipid preparation from egg yolk, called super lecithin, for the production of a medicine or as an active substance of a non-steroidal anti-inflammatory drug for use in the treatment, alleviation or prevention of inflammation and inflammatory diseases, especially such as cancer, obesity, diabetes, hypertension. arterial, atherosclerosis. The solution also includes the use of super lecithin as a pharmaceutical, dietary supplement, nutritional supplement or as a component of complex preparations for use in prevention and supplementation of standard therapy for the treatment of these diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408335A PL227388B1 (en) | 2014-05-23 | 2014-05-23 | Application of phospholipide preparation from egg yolk |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408335A PL227388B1 (en) | 2014-05-23 | 2014-05-23 | Application of phospholipide preparation from egg yolk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL408335A1 true PL408335A1 (en) | 2015-12-07 |
| PL227388B1 PL227388B1 (en) | 2017-11-30 |
Family
ID=54776567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL408335A PL227388B1 (en) | 2014-05-23 | 2014-05-23 | Application of phospholipide preparation from egg yolk |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL227388B1 (en) |
-
2014
- 2014-05-23 PL PL408335A patent/PL227388B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL227388B1 (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018076601A2 (en) | oral pharmaceutical formulation, methods for treating a patient, and use of a formulation | |
| EA201791702A1 (en) | THERAPEUTIC TOOLS ON THE BASIS OF GLYCANS AND RELATED METHODS | |
| BR112016007536A2 (en) | corresponding compounds, compositions and uses for the prevention and / or treatment of dyslipidemia | |
| EA201890767A1 (en) | C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER APPLICATIONS | |
| PH12017502375A1 (en) | Method of treating inflammation using natural compounds and/or diet | |
| EA201591371A1 (en) | Pyridine derivatives as easily degraded inhibitors ROCK | |
| EP4570314A3 (en) | Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure | |
| CL2019001586A1 (en) | Insulin containing pharmaceutical compositions. | |
| GT201400059A (en) | DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
| EA201791537A1 (en) | PHARMACEUTICAL COMPOSITION ON THE BASIS OF NANOPARTICLES OF DOCETAXEL-ALBUMIN, METHOD FOR ITS PREPARATION AND ITS APPLICATION | |
| CY1119957T1 (en) | TREATMENT OF PATIENTS WITH THE USE OF ANNOUNCED PHARMACEUTICAL PREPARATION | |
| BR112018000242A2 (en) | nutritional compositions containing phosphatidylethanolamine, sphingomyelin and doco-hexaenoic acid | |
| DOP2015000005A (en) | DERIVATIVES OF ESTRA 1,3,5 (10), 16 TETRAENE 3 SUBSTITUTES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
| MX2019001579A (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING INHIBITORS OF PROTEIN KINASE AKT. | |
| BR112017000898A2 (en) | high purity oritavancin and its production method | |
| EA201691570A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING DIAMINO-HETEROCYCLIC CARBOXAMIDE COMPOUND AS AN ACTIVE INGREDIENT | |
| PH12020550532A1 (en) | Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor | |
| MX364528B (en) | Withanolides useful for the treatment of neurodegenerative diseases. | |
| EA201790622A1 (en) | THERAPEUTIC AND NUTRITIONAL COMPOSITIONS FOR FUNCTIONAL WORKING DISABILITIES OF THE DIGESTIVE SYSTEM | |
| CO2017001899A2 (en) | Cancer treatment with alpha-amylase inhibitor in companion animals | |
| BR112018008076A2 (en) | lapachone derivatives containing two redox centers and methods of using them | |
| MA40645A (en) | INULIN-BASED PREBIOTIC PREPARATION | |
| EA202090666A1 (en) | APPLICATION OF BENZOATE-CONTAINING COMPOSITION FOR TREATMENT OF GLYCINE ENCEPHALOPATHY | |
| PL408335A1 (en) | Application of phospholipide preparation from egg yolk | |
| BR112019017314A2 (en) | pharmaceutical compositions for combination therapy |